ND Biosciences is an EPFL spinoff that was founded to develop next-generation therapeutics and diagnostics for neurodegenerative diseases (NDs), such as Parkinson’s and Alzheimer’s Disease.

ND Biosciences has developed unique technologies that allow for the first time reproducing the biochemical, structural, and functional properties of pathological protein aggregates observed in NDs. These unique capabilities are used by ND Biosciences to develop therapies that can prevent the initiation of protein aggregation, and that can clear and neutralize the activities of existing protein aggregates, including their ability to spread and propagate pathology in the brain.

This is accomplished using ND Biosciences’ integrated and proprietary platforms that allow:

1.               Reverse-engineering the complexity of disease-relevant protein aggregate targets observed in the brains of patients suffering from NDs under controlled conditions

2.               Faithfully recapitulating key processes underlying the formation of protein pathologies and neurodegeneration in a set of validated neuronal models, which ND has developed into an integrated platform for target validation and drug discovery

3.               Developing novel companion diagnostic assays and imaging agents that capture the diversity of pathological species detected in biological fluids and brains of patients, for accurate assessment of target engagement and efficacy of ND Biosciences’ novel therapies